

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2024 April 15; 16(4): 1091-1675



EDITORIAL

- 1091** Parallel pathways: A chronicle of evolution in rectal and breast cancer surgery
Pesce A, Fabbri N, Iovino D, Feo CV
- 1097** Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now
Sukowati CHC, Jayanti S, Turyadi T, Muljono DH, Tiribelli C

REVIEW

- 1104** Novel milestones for early esophageal carcinoma: From bench to bed
Qi JH, Huang SL, Jin SZ
- 1119** Colorectal cancer screening: A review of current knowledge and progress in research
Lopes SR, Martins C, Santos IC, Teixeira M, Gamito É, Alves AL
- 1134** New avenues for the treatment of immunotherapy-resistant pancreatic cancer
Silva LGO, Lemos FFB, Luz MS, Rocha Pinheiro SL, Calmon MDS, Correa Santos GL, Rocha GR, de Melo FF

MINIREVIEWS

- 1154** Present situation of minimally invasive surgical treatment for early gastric cancer
Li CY, Wang YF, Luo LK, Yang XJ
- 1166** Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract
Díaz-López S, Jiménez-Castro J, Robles-Barraza CE, Ayala-de Miguel C, Chaves-Conde M
- 1180** Esophageal cancer screening, early detection and treatment: Current insights and future directions
Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, Chen XD, Zhang TT, Miao YD, Zhang F

ORIGINAL ARTICLE

Retrospective Cohort Study

- 1192** Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early recurrence of hepatocellular carcinoma after radical resection
Chen JP, Yang RH, Zhang TH, Liao LA, Guan YT, Dai HY
- 1204** Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center
Zhu CL, Peng LZ

Retrospective Study

- 1213 Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers
Nie GL, Yan J, Li Y, Zhang HL, Xie DN, Zhu XW, Li X
- 1227 Predictive modeling for postoperative delirium in elderly patients with abdominal malignancies using synthetic minority oversampling technique
Hu WJ, Bai G, Wang Y, Hong DM, Jiang JH, Li JX, Hua Y, Wang XY, Chen Y
- 1236 Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Ma KP, Fu JX, Duan F, Wang MQ
- 1248 Should we perform sigmoidoscopy for colorectal cancer screening in people under 45 years?
Leong W, Guo JQ, Ning C, Luo FF, Jiao R, Yang DY
- 1256 Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma
Ren S, Qian LC, Cao YY, Daniels MJ, Song LN, Tian Y, Wang ZQ
- 1268 Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model
He XX, Du B, Wu T, Shen H

Clinical Trials Study

- 1281 Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers
Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD

Observational Study

- 1296 Computed tomography radiogenomics: A potential tool for prediction of molecular subtypes in gastric stromal tumor
Yin XN, Wang ZH, Zou L, Yang CW, Shen CY, Liu BK, Yin Y, Liu XJ, Zhang B
- 1309 Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study
Nong HY, Cen YY, Qin M, Qin WQ, Xie YX, Li L, Liu MR, Ding K
- 1319 Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study
Chen ZT, Ding CC, Chen KL, Gu YJ, Lu CC, Li QY
- 1334 Is recovery enhancement after gastric cancer surgery really a safe approach for elderly patients?
Li ZW, Luo XJ, Liu F, Liu XR, Shu XP, Tong Y, Lv Q, Liu XY, Zhang W, Peng D
- 1344 Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels
Yang CY, Guo LM, Li Y, Wang GX, Tang XW, Zhang QL, Zhang LF, Luo JY

- 1361** Effectiveness of fecal DNA syndecan-2 methylation testing for detection of colorectal cancer in a high-risk Chinese population

Luo WF, Jiao YT, Lin XL, Zhao Y, Wang SB, Shen J, Deng J, Ye YF, Han ZP, Xie FM, He JH, Wan Y

Clinical and Translational Research

- 1374** Clinical and socioeconomic determinants of survival in biliary tract adenocarcinomas

Sahyoun L, Chen K, Tsay C, Chen G, Protiva P

- 1384** Risk factors, prognostic factors, and nomograms for distant metastasis in patients with diagnosed duodenal cancer: A population-based study

Shang JR, Xu CY, Zhai XX, Xu Z, Qian J

- 1421** NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer

Xu YJ, Huo YC, Zhao QT, Liu JY, Tian YJ, Yang LL, Zhang Y

Basic Study

- 1437** Curcumin inhibits the growth and invasion of gastric cancer by regulating long noncoding RNA AC022424.2

Wang BS, Zhang CL, Cui X, Li Q, Yang L, He ZY, Yang Z, Zeng MM, Cao N

- 1453** MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual-specificity tyrosine(Y)-regulated kinase 1A

Shen MZ, Zhang Y, Wu F, Shen MZ, Liang JL, Zhang XL, Liu XJ, Li XS, Wang RS

- 1465** Human β -defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506

Zhao YX, Cui Y, Li XH, Yang WH, An SX, Cui JX, Zhang MY, Lu JK, Zhang X, Wang XM, Bao LL, Zhao PW

- 1479** FAM53B promotes pancreatic ductal adenocarcinoma metastasis by regulating macrophage M2 polarization

Pei XZ, Cai M, Jiang DW, Chen SH, Wang QQ, Lu HM, Lu YF

- 1500** Transcriptome sequencing reveals novel biomarkers and immune cell infiltration in esophageal tumorigenesis

Sun JR, Chen DM, Huang R, Wang RT, Jia LQ

- 1514** Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma

Pan Y, Zhang YR, Wang LY, Wu LN, Ma YQ, Fang Z, Li SB

- 1532** Two missense STK11 gene variations impaired LKB1/adenosine monophosphate-activated protein kinase signaling in Peutz-Jeghers syndrome

Liu J, Zeng SC, Wang A, Cheng HY, Zhang QJ, Lu GX

- 1547** Long noncoding RNAs HAND2-AS1 ultrasound microbubbles suppress hepatocellular carcinoma progression by regulating the miR-873-5p/tissue inhibitor of matrix metalloproteinase-2 axis

Zou Q, Wang HW, Di XL, Li Y, Gao H

- 1564** Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription

Li SN, Yang S, Wang HQ, Hui TL, Cheng M, Zhang X, Li BK, Wang GY

SYSTEMATIC REVIEWS

- 1578** Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis

Nakamura ET, Park A, Pereira MA, Kikawa D, Tustumi F

- 1596** Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

Farooq HZ, James M, Abbott J, Oyibo P, Divall P, Choudhry N, Foster GR

META-ANALYSIS

- 1613** Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers

Zhang XM, Yang T, Xu YY, Li BZ, Shen W, Hu WQ, Yan CW, Zong L

- 1626** Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis

Jiang KL, Wang XX, Liu XJ, Guo LK, Chen YQ, Jia QL, Yang KM, Ling JH

CASE REPORT

- 1647** Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature

Chu JH, Huang LY, Wang YR, Li J, Han SL, Xi H, Gao WX, Cui YY, Qian MP

- 1660** Clinical pathological characteristics of "crawling-type" gastric adenocarcinoma cancer: A case report

Xu YW, Song Y, Tian J, Zhang BC, Yang YS, Wang J

- 1668** Primary pancreatic peripheral T-cell lymphoma: A case report

Bai YL, Wang LJ, Luo H, Cui YB, Xu JH, Nan HJ, Yang PY, Niu JW, Shi MY

ABOUT COVER

Peer Reviewer of *World Journal of Gastrointestinal Oncology*, Lie Zheng, Director, Professor, Department of Gastroenterology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an 730000, Shaanxi Province, China. xinliwen696@126.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

April 15, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Observational Study

Is recovery enhancement after gastric cancer surgery really a safe approach for elderly patients?

Zi-Wei Li, Xiao-Juan Luo, Fei Liu, Xu-Rui Liu, Xin-Peng Shu, Yue Tong, Quan Lv, Xiao-Yu Liu, Wei Zhang, Dong Peng

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Sugimura H, Japan

Received: December 18, 2023

Peer-review started: December 18, 2023

First decision: January 4, 2024

Revised: January 15, 2024

Accepted: February 20, 2024

Article in press: February 20, 2024

Published online: April 15, 2024



Zi-Wei Li, Fei Liu, Xu-Rui Liu, Xin-Peng Shu, Yue Tong, Quan Lv, Xiao-Yu Liu, Wei Zhang, Dong Peng, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Xiao-Juan Luo, Department of Endoscopy Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400012, China

Corresponding author: Dong Peng, PhD, Adjunct Associate Professor, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, China. carry_dong@126.com

Abstract

BACKGROUND

This study aimed to evaluate the safety of enhanced recovery after surgery (ERAS) in elderly patients with gastric cancer (GC).

AIM

To evaluate the safety of ERAS in elderly patients with GC.

METHODS

The PubMed, EMBASE, and Cochrane Library databases were used to search for eligible studies from inception to April 1, 2023. The mean difference (MD), odds ratio (OR) and 95% confidence interval (95%CI) were pooled for analysis. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale scores. We used Stata (V.16.0) software for data analysis.

RESULTS

This study consists of six studies involving 878 elderly patients. By analyzing the clinical outcomes, we found that the ERAS group had shorter postoperative hospital stays (MD = -0.51, $I^2 = 0.00\%$, 95%CI = -0.72 to -0.30, $P = 0.00$); earlier times to first flatus (defecation; MD = -0.30, $I^2 = 0.00\%$, 95%CI = -0.55 to -0.06, $P = 0.02$); less intestinal obstruction (OR = 3.24, $I^2 = 0.00\%$, 95%CI = 1.07 to 9.78, $P = 0.04$); less nausea and vomiting (OR = 4.07, $I^2 = 0.00\%$, 95%CI = 1.29 to 12.84, $P = 0.02$); and less gastric retention (OR = 5.69, $I^2 = 2.46\%$, 95%CI = 2.00 to 16.20, $P = 0.00$). Our results showed that the conventional group had a greater mortality rate than the ERAS group (OR = 0.24, $I^2 = 0.00\%$, 95%CI = 0.07 to 0.84, $P = 0.03$). However, there was no statistically significant difference in major complications

between the ERAS group and the conventional group (OR = 0.67, I^2 = 0.00%, 95%CI = 0.38 to 1.18, P = 0.16).

CONCLUSION

Compared to those with conventional recovery, elderly GC patients who received the ERAS protocol after surgery had a lower risk of mortality.

Key Words: Enhanced recovery after surgery; Gastric cancer; Elderly; Mortality

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study was the first pooling up analysis to evaluate the safety of enhanced recovery after surgery in elderly patients with gastric cancer. In conclusion, compared to those with conventional recovery, elderly gastric cancer (GC) patients who received the enhanced recovery after surgery (ERAS) protocol after surgery had a lower risk of mortality. The ERAS protocol was determined to be safe in elderly patients with GC.

Citation: Li ZW, Luo XJ, Liu F, Liu XR, Shu XP, Tong Y, Lv Q, Liu XY, Zhang W, Peng D. Is recovery enhancement after gastric cancer surgery really a safe approach for elderly patients? *World J Gastrointest Oncol* 2024; 16(4): 1334-1343

URL: <https://www.wjgnet.com/1948-5204/full/v16/i4/1334.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v16.i4.1334>

INTRODUCTION

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide[1, 2]. It has been reported that more than 50% of GC occur in East Asian countries[3,4]. Among the various treatments available, surgery is the cornerstone of treatment for patients with GC[5-7]. Although the development of surgical techniques has advanced, postoperative complications and mortality are still high[8]. According to a previous study, the postoperative mortality rate is as high as 4%[9]. Therefore, how to reduce postoperative complications and mortality has become the focus of surgeons.

Enhanced recovery after surgery (ERAS) is primarily defined as a multimodal strategy that optimizes perioperative management to improve surgical outcomes and enhance postoperative recovery[10]. This strategy includes preoperative carbohydrate loading, early oral feeding, and early postoperative activity[11]. The ERAS protocol has been proven to reduce the rate of postoperative complications and shorten the postoperative hospital stay for patients with digestive tract cancer [12,13].

With the gradual aging of the population, the number of elderly patients with GC is also increasing[14-16]. Elderly patients usually have a poor physiological function, more comorbidities, and slower recovery after surgery. The use of the ERAS protocol in elderly patients with GC has been reported[17]. However, for elderly patients with GC, there is no convincing evidence that the ERAS protocol is a safe and effective measure. Therefore, the purpose of this study was to evaluate the safety of ERAS in older patients with GC.

MATERIALS AND METHODS

This study was conducted by the PRISMA statement[18].

Search strategy

The PubMed, EMBASE, and Cochrane Library databases were searched from inception to April 1, 2023. The following keywords related to ERAS were used for the search: “enhanced recovery after surgery” OR “ERAS” OR “enhanced recovery” OR “enhanced recovery protocols” OR “enhanced rehabilitation” OR “perioperative care” OR “conventional care” OR “early recovery” OR “fast track” OR “multimodal perioperative protocol” OR “standard care” OR “care standard”. As for GC, the search strategy was “gastric cancer” OR “gastric carcinoma” OR “gastric neoplasms” OR “stomach cancer” OR “stomach carcinoma” OR “stomach neoplasms”. As for older, the searching strategy was “aged” OR “older” OR “older adult” OR “older patients” OR “elderly”. Then, we combined these items with “AND”. The search was limited to title and abstract. The language available was English. And two authors performed the search independently.

Inclusion and exclusion criteria

The studies were included in this study if they met the following criteria: (1) Elderly patients who underwent GC surgery; (2) the comparison between the ERAS group and the conventional group was reported; and (3) postoperative complications were reported. The exclusion criteria of this study were as follows: (1) Conferences, reviews, letters, comments, or

case reports, duplicated publication data; and (2) insufficient data for analysis. All disagreements about inclusion and exclusion were solved by group discussion.

Study selection

Two authors searched the database independently. First, after removing the duplicate records, and then the titles and abstracts were screened. Second, the full texts were evaluated for eligibility based on the inclusion and exclusion criteria. The final judgment was made after the group discussion.

Definition

Postoperative complications of this study were classified according to the Clavien-Dindo classification and severe postoperative complications were defined as grades $\geq$ III[19].

Data extraction

The data of this study were extracted as follows: (1) Studies' information included the publication year, the first author's name, country, sample size, study design; (2) patients' baseline information including age, sex, body mass index (BMI), smoking, American Society of Anesthesiologists (ASA) grade, TMN stage, type of surgery, type of reconstruction, neoadjuvant chemotherapy, cardiovascular system disease, respiratory system diseases, diabetes and renal system diseases; and (3) postoperative complications included operative time, postoperative hospital stay, blood loss, bleeding, time to first flatus(defecation), anastomotic leakage, intestinal obstruction, pulmonary related complication, cardiovascular-related complication, nausea and vomiting, gastric retention, urinary retention, incision infection, urinary tract infection, reoperation, readmission, major complications and mortality.

Quality assessment

The Newcastle-Ottawa Scale (NOS), which had a score ranging from zero to nine points, was used to assess the quality of the enrolled studies[20]. A study with a score of nine points was considered high quality, a study with a score of seven to eight points was considered medium quality, and a study with six or fewer was considered low quality.

Statistical analysis

The mean differences (MDs) and 95% confidence intervals (95% CIs) were calculated for continuous variables. Odds ratios (ORs) and 95% CIs were calculated for the postoperative complications. Statistical heterogeneity was assessed by using the value of I^2 and the result of the chi-squared test. If $I^2 > 50\%$, it was considered high heterogeneity, the random effect model was used and $P < 0.1$ was considered statistically significant[21]. The random effect model was used in this article. Funnel plots and Egger tests were also used to observe the heterogeneity of studies and publication bias. This study was performed with Stata (V.16.0).

RESULTS

Study selection

There were 70 studies in the database. Twenty-four studies were included in PubMed, 46 studies were included in Embase, and 0 studies were included in Cochrane Library. After deleting duplicate studies and study types that not meet the requirements, 35 studies were left for record screening. Then, browsing the titles and abstracts, leaving 22 studies for full text review. Finally, there were six studies[17,22-26] were included for analysis (Figure 1).

Baseline characteristics of all studies

This study consisted by six studies involving 878 participants. These studies were published from 2015 to 2022 and the study period was from 2010 to 2021. There were four retrospective studies and two prospective studies. The NOS scores and baseline characteristics of included studies were summarized in Table 1.

Clinical characteristics between the ERAS group and the conventional group

By comparing the clinical characteristics, no significant differences were found in age (MD = 0.06, $I^2 = 46.03\%$, 95% CI = -0.18 to 0.30, $P = 0.65$), sex (OR = 0.95, $I^2 = 0.00\%$, 95% CI = 0.71 to 1.26, $P = 0.71$), BMI (MD = -0.05, $I^2 = 0.00\%$, 95% CI = -0.22 to 0.12, $P = 0.54$), smoking (OR = 1.00, $I^2 = 0.00\%$, 95% CI = 0.69 to 1.44, $P = 0.98$), ASA grade (≥ 2) (OR = 1.03, $I^2 = 0.00\%$, 95% CI = 0.64 to 1.64, $P = 0.92$), Tumor Node Metastasis (TNM) stage II (OR = 1.03, $I^2 = 0.00\%$, 95% CI = 0.69 to 1.54, $P = 0.88$), TNM stage III (OR = 0.89, $I^2 = 0.00\%$, 95% CI = 0.64 to 1.23, $P = 0.47$), distal gastrectomy (OR = 1.28, $I^2 = 0.00\%$, 95% CI = 0.74 to 2.22, $P = 0.38$), proximal gastrectomy (OR = 1.36, $I^2 = 0.00\%$, 95% CI = 0.62 to 2.98, $P = 0.44$), Billroth-I reconstruction (OR = 1.25, $I^2 = 0.00\%$, 95% CI = 0.59 to 2.67, $P = 0.56$), Billroth-II reconstruction (OR = 1.17, $I^2 = 0.00\%$, 95% CI = 0.62 to 2.22, $P = 0.63$), cardiovascular system disease (OR = 1.00, $I^2 = 0.00\%$, 95% CI = 0.72 to 1.39, $P = 1.00$), respiratory system diseases (OR = 1.04, $I^2 = 15.67\%$, 95% CI = 0.62 to 1.73, $P = 0.89$), Renal system diseases (OR = 0.92, $I^2 = 0.00\%$, 95% CI = 0.47 to 1.82, $P = 0.82$) and diabetes (OR = 0.73, $I^2 = 12.29\%$, 95% CI = 0.48 to 1.12, $P = 0.15$). We found that the conventional group had more neoadjuvant chemotherapy patients (OR = 2.74, $I^2 = 0.00\%$, 95% CI = 1.64 to 4.57, $P = 0.00$) than the ERAS group (Table 2).

Table 1 Baseline characteristics of included studies

Ref.	Country	Study date	Study type	Sample size		Years old		Age range	NOS
				ERAS	Conventional	ERAS	Conventional		
Xiao <i>et al</i> [17], 2022	China	2019-2021	Prospective	50	50	72.7 ± 2.7	72.3 ± 2.3	≥ 70	8
Franceschilli M <i>et al</i> [22], 2022	Italy	2013-2021	Retrospective	23	21	69.7 ± 9.8	64.3 ± 6.7	≥ 18	7
Weindelmayer <i>et al</i> [23], 2021	Italy	2015-2019	Retrospective	248	103	68	70	60-78	7
Cao S <i>et al</i> [24], 2021	China	2014-2018	Prospective	85	86	70.8 ± 3.4	71.4 ± 3.7	65-85	7
Liu <i>et al</i> [25], 2016	China	2014-2015	Retrospective	42	42	68.5 ± 4.5	69.5 ± 5.4	≥ 60	8
Bu <i>et al</i> [26], 2015	China	2010-2014	Retrospective	64	64	80.1 ± 4.0	79.6 ± 3.5	45-90	8

ERAS: Enhanced recovery after surgery; NOS: Newcastle-Ottawa Scales.

Table 2 Summary of characteristics between the enhanced recovery after surgery group and the conventional group

Characteristics	Studies	Participants (ERAS/conventional)	Odds ratio/mean difference (95%CI)	Heterogeneity
Age (yr)	5	264/263	0.06 (-0.18, 0.30); $P = 0.65$	$I^2 = 46.03\%$; $P = 0.12$
Sex, female	6	512/366	0.95 (0.71, 1.26); $P = 0.71$	$I^2 = 0.00\%$; $P = 0.63$
BMI (kg/m ²)	5	264/263	-0.05 (-0.22, 0.12); $P = 0.54$	$I^2 = 0.00\%$; $P = 0.45$
Smoking	2	333/189	1.00 (0.69, 1.44); $P = 0.98$	$I^2 = 0.00\%$; $P = 0.62$
ASA, ≥2	4	222/221	1.03 (0.64, 1.64); $P = 0.92$	$I^2 = 0.00\%$; $P = 0.58$
TNM stage				
I	6	Reference	Reference	Reference
II	6	263/215	1.03 (0.69, 1.54); $P = 0.88$	$I^2 = 0.00\%$; $P = 0.81$
III	6	399/293	0.89 (0.64, 1.23); $P = 0.47$	$I^2 = 0.00\%$; $P = 0.46$
Type of surgery				
Total	3	Reference	Reference	Reference
Distal	3	122/126	1.28 (0.74, 2.22); $P = 0.38$	$I^2 = 0.00\%$; $P = 0.97$
Proximal	3	69/72	1.36 (0.62, 2.98); $P = 0.44$	$I^2 = 0.00\%$; $P = 0.38$
Type of reconstruction				
Roux-en-Y	2	Reference	Reference	Reference
Billroth-I	2	56/58	1.25 (0.59, 2.67); $P = 0.56$	$I^2 = 0.00\%$; $P = 0.40$
Billroth-II	2	78/80	1.17 (0.62, 2.22); $P = 0.63$	$I^2 = 0.00\%$; $P = 0.92$
Neoadjuvant chemotherapy	2	271/124	2.74 (1.64, 4.57); $P = 0.00*$	$I^2 = 0.00\%$; $P = 0.45$
Comorbidities				
Cardiovascular system disease	4	462/316	1.00 (0.72, 1.39); $P = 1.00$	$I^2 = 0.00\%$; $P = 0.86$
Respiratory system diseases	4	462/316	1.04 (0.62, 1.73); $P = 0.89$	$I^2 = 15.67\%$; $P = 0.31$
Renal system diseases	2	333/189	0.92 (0.47, 1.82); $P = 0.82$	$I^2 = 0.00\%$; $P = 0.57$
Diabetes	4	462/316	0.73 (0.48, 1.12); $P = 0.15$	$I^2 = 12.29\%$; $P = 0.34$

ASA: American Society of Anesthesiologists; TMN: Tumor Node Metastasis; 95%CI: 95% confidence intervals; ERAS: Enhanced recovery after surgery.

Clinical outcomes between the ERAS group and the conventional group

We found that the ERAS group had shorter postoperative hospital stays (MD = -0.51, $I^2 = 0.00\%$, 95%CI = -0.72 to -0.30, $P = 0.00$), earlier times to first flatus(defecation; MD = -0.30, $I^2 = 0.00\%$, 95%CI = -0.55 to -0.06, $P = 0.02$), less intestinal obstruction (OR = 3.24, $I^2 = 0.00\%$, 95%CI = 1.07 to 9.78, $P = 0.04$), less nausea and vomiting (OR = 4.07, $I^2 = 0.00\%$, 95%CI = 1.29 to 12.84, $P = 0.02$), less gastric retention (OR = 5.69, $I^2 = 2.46\%$, 95%CI = 2.00 to 16.20, $P = 0.00$). However, no




Figure 1 Flowchart of study selection.

significant differences were found in operative times (MD = 0.05, $I^2 = 25.46\%$, 95%CI = -0.16 to 0.26, $P = 0.64$), operative blood loss (OR = -0.09, $I^2 = 0.00\%$, 95%CI = -0.36 to 0.17, $P = 0.49$), postoperative bleeding (OR = 0.47, $I^2 = 0.00\%$, 95%CI = 0.08 to 2.23, $P = 0.39$), anastomotic leakage (OR = 1.10, $I^2 = 0.00\%$, 95%CI = 0.40 to 3.03, $P = 0.86$), pulmonary related complication (OR = 0.76, $I^2 = 0.00\%$, 95%CI = 0.43 to 1.35, $P = 0.35$), cardiovascular-related complication (OR = 0.53, $I^2 = 0.00\%$, 95%CI = 0.25 to 1.11, $P = 0.09$), urinary retention (OR = 0.68, $I^2 = 0.00\%$, 95%CI = 0.25 to 1.88, $P = 0.46$), incision infection (OR = 2.26, $I^2 = 0.00\%$, 95%CI = 0.49 to 10.41, $P = 0.30$), urinary tract infection (OR = 0.52, $I^2 = 0.00\%$, 95%CI = 0.18 to 1.46, $P = 0.21$), reoperation (OR = 0.46, $I^2 = 29.68\%$, 95%CI = 0.07 to 3.00, $P = 0.42$) and readmission (OR = 1.42, $I^2 = 47.15\%$, 95%CI = 0.46 to 4.33, $P = 0.54$; Table 3).

Mortality between the ERAS group and the conventional group

There were four studies[17,22-24] reporting the mortality. After analyzing the data, we found that the conventional group had a greater mortality rate than the ERAS group. (OR = 0.24, $I^2 = 0.00\%$, 95%CI = 0.07 to 0.84, $P = 0.03$; Figure 2).

Major complications between the ERAS group and the conventional group

There were three studies[17,23,24] reported major complications in elderly patients with GC who underwent surgery. We found that there was no statistically significant difference in the major complications between the ERAS group and the conventional group (OR = 0.67, $I^2 = 0.00\%$, 95%CI = 0.38 to 1.18, $P = 0.16$; Figure 3).

Publication bias

Visual inspection of symmetric funnel plots was used to analyze publication bias for the including studies. A funnel plot was established to reflect the heterogeneity of readmission rates (Figure 4).

DISCUSSION

This study consists of six studies involving 878 elderly patients who underwent GC surgery. By analyzing the clinical outcomes of the ERAS group and the conventional group, we found that the ERAS group had a lower mortality rate than the conventional group. However, there was no statistically significant difference in major complications between the two groups.


ERAS was gradually developed to strengthen perioperative management and accelerate patients' postoperative recovery[27]. Recently, ERAS has been successfully applied to patients with a variety of cancers, including colorectal cancer, bladder cancer and GC[28-30]. Due to preexisting physical injuries or associated comorbidities, elderly patients are more likely to experience higher postoperative complication rates and mortality than relatively healthy and younger patients are[31]. For ERAS to be implemented in elderly people, surgeons first follow the principle of safety.

In recent years, many studies have reported the application of ERAS in elderly patients with GC and confirmed its positive effects[17,22-24]. However, there has been no definitive conclusion regarding postoperative mortality. Xiao *et al* [17] divided elderly cancer patients (aged > 70 years) who underwent GC surgery into an ERAS group and a conventional

Table 3 Operative and postoperative complications between enhanced recovery after surgery group and conventional group

Characteristics	Studies	Participants (ERAS/conventional)	Odds ratio/mean difference (95%CI)	Heterogeneity
Operative time (min)	4	241/242	0.05 (-0.16, 0.26); $P = 0.64$	$I^2 = 25.46\%$; $P = 0.26$
Postoperative hospital stays	10	179/177	-0.51 (-0.72, -0.30); $P = 0.00^a$	$I^2 = 0.00\%$; $P = 0.52$
Operative blood loss (mL)	2	108/108	-0.09 (-0.36, 0.17); $P = 0.49$	$I^2 = 0.00\%$; $P = 0.41$
Postoperative bleeding	2	108/107	0.47 (0.08, 2.23); $P = 0.39$	$I^2 = 0.00\%$; $P = 0.93$
Time to first flatus(defecation)	4	129/127	-0.30 (-0.55, -0.06); $P = 0.02^a$	$I^2 = 0.00\%$; $P = 0.74$
Anastomotic leakage	5	470/324	1.10 (0.40, 3.03); $P = 0.86$	$I^2 = 0.00\%$; $P = 0.59$
Intestinal obstruction	3	156/156	3.24 (1.07, 9.78); $P = 0.04^a$	$I^2 = 0.00\%$; $P = 0.91$
Pulmonary related complication	6	512/366	0.76 (0.43, 1.35); $P = 0.35$	$I^2 = 0.00\%$; $P = 0.87$
Cardiovascular related complication	2	333/189	0.53 (0.25, 1.11); $P = 0.09$	$I^2 = 0.00\%$; $P = 0.93$
Nausea and vomiting	2	106/106	4.07 (1.29, 12.84); $P = 0.02^a$	$I^2 = 0.00\%$; $P = 0.52$
Gastric retention	2	106/106	5.69 (2.00, 16.20); $P = 0.00^a$	$I^2 = 2.46\%$; $P = 0.31$
Urinary retention	2	106/106	0.68 (0.25, 1.88); $P = 0.46$	$I^2 = 0.00\%$; $P = 0.57$
Incision infection	2	106/106	2.26 (0.49, 10.41); $P = 0.30$	$I^2 = 0.00\%$; $P = 0.83$
Urinary tract infection	2	106/106	0.52 (0.18, 1.46); $P = 0.21$	$I^2 = 0.00\%$; $P = 0.86$
Reoperation	3	356/210	0.46 (0.07, 3.00); $P = 0.42$	$I^2 = 29.68\%$; $P = 0.24$
Readmission	5	470/324	1.42 (0.46, 4.33); $P = 0.54$	$I^2 = 47.15\%$; $P = 0.11$

95%CI: 95% confidence intervals; ERAS: Enhanced recovery after surgery.

^a $P < 0.05$.

Random-effects DerSimonian-Laird model

Figure 2 Comparing major complications between the enhanced recovery after surgery group and the conventional group. OR: Odds ratio; 95%CI: 95% confidence interval.

group. However, no significant difference in mortality was found between the two groups. Similarly, Cao *et al* [24] reported that there was no significant difference in the mortality rate between the ERAS group and the conventional group in their study. However, Weindelmayer *et al* [23] held the opposite view. Their research involving elderly patients with GC suggested that the mortality rate in the ERAS group was lower than that in the traditional group. Therefore, the purpose of this study was to evaluate the specific effect of ERAS on older patients with GC. It was necessary for us to determine whether ERAS could be safely implemented in elderly patients.

Our study showed that the ERAS group had a shorter postoperative hospital stays; earlier time to first flatus(defecation); less intestinal obstruction; less nausea and vomiting; and less gastric retention. And the conventional group had a greater mortality rate than the ERAS group. Our research indicated that the ERAS protocol was safe for elderly patients with GC. However, there was no statistically significant difference in major complications between the two groups. This may have been because elderly patients might have a lower adherence to ERAS measures, which reduces the effectiveness of the protocol [32].




Figure 3 Comparing mortality between the enhanced recovery after surgery group and the conventional group. OR: Odds ratio; 95%CI: 95% confidence interval.




Figure 4 Funnel plot of readmission. OR: Odds ratio; 95%CI: 95% confidence interval.

For all we know, this study was the first pooling-up analysis to evaluate the safety of ERAS for elderly patients with GC. This study has several limitations. First, this study only included six articles, which was relatively small. Second, the age range of the elderly individuals included in the study varied. Third, this study lacked certain short-term and long-term outcomes. Fourth, we could not determine the impact of ERAS on younger or ordinary aged patients. Therefore, comprehensive and high-quality randomized controlled trials should be performed to further confirm our findings.

CONCLUSION

Compared to those with conventional recovery, elderly GC patients who received the ERAS protocol after surgery had a lower risk of mortality. The ERAS protocol was determined to be safe in elderly patients with GC.

ARTICLE HIGHLIGHTS

Research background

This study aimed to evaluate the safety of enhanced recovery after surgery (ERAS) in elderly patients with gastric cancer (GC).

Research motivation

Elderly patients usually have a poor physiological function, more comorbidities, and slow recovery after surgery. Although the application of ERAS protocol in elderly patients with GC has been reported. For elderly patients with GC, there is no convincing evidence that the ERAS protocol is a safe and effective measure.

Research objectives

It was necessary for us to find out whether ERAS could be safely implemented in elderly patients.

Research methods

The PubMed, EMBASE, and Cochrane Library databases were used to search for eligible studies from inception to April 1, 2023. The mean difference (MD), odds ratio (OR) and 95% confidence interval (95%CI) were pooled for analysis. The quality of the included studies was evaluated using the Newcastle-Ottawa Scale scores. We used Stata (V.16.0) software for data analysis.

Research results

This study consists of six studies involving 878 elderly patients. By analyzing the clinical outcomes, we found that the ERAS group had shorter postoperative hospital stays (MD = -0.51, $I^2 = 0.00\%$, 95%CI = -0.72 to -0.30, $P = 0.00$); earlier times to first flatus(defecation; MD = -0.30, $I^2 = 0.00\%$, 95%CI = -0.55 to -0.06, $P = 0.02$); less intestinal obstruction (OR = 3.24, $I^2 = 0.00\%$, 95%CI = 1.07 to 9.78, $P = 0.04$); less nausea and vomiting (OR = 4.07, $I^2 = 0.00\%$, 95%CI = 1.29 to 12.84, $P = 0.02$); and less gastric retention (OR = 5.69, $I^2 = 2.46\%$, 95%CI = 2.00 to 16.20, $P = 0.00$). Our results showed the conventional group had a greater mortality rate than the ERAS group. (OR = 0.24, $I^2 = 0.00\%$, 95%CI = 0.07 to 0.84, $P = 0.03$). However, there was no statistically significant difference in the major complications between the ERAS group and the conventional group (OR = 0.67, $I^2 = 0.00\%$, 95%CI = 0.38 to 1.18, $P = 0.16$).

Research conclusions

Compared to those with conventional recovery, elderly GC patients who received the ERAS protocol after surgery had a lower risk of mortality.

Research perspectives

Compared to those with conventional recovery, elderly GC patients who received the ERAS protocol after surgery was associated with a lower risk of mortality. ERAS protocol was safe in elderly patients with GC.

ACKNOWLEDGEMENTS

We acknowledge all of the authors whose publications are referred to in our article.

FOOTNOTES

Co-first authors: Zi-Wei Li and Xiao-Juan Luo.

Author contributions: Zi-Wei Li and Xiao-Juan Luo have contributed equally to this work. Data extraction, Xiao-Yu Liu, Xiao-Juan Luo, Xin-Peng Shu, Yue Tong, Quan Lv, and Fei Liu; quality assessments, Xu-Rui Liu and Wei Zhang; data analysis, Zi-Wei Li and Quan Lv; writing-origin draft, Zi-Wei Li; writing-review and editing, Zi-Wei Li, Dong Peng. All authors read and approved the final manuscript. Li ZW and Luo XJ contributed equally to this work as co-first authors. The choice of these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Li ZW and Luo XJ as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.

Supported by Chongqing Medical University Program for Youth Innovation in Future Medicine, No. W0190.

Institutional review board statement: The data used in this study were obtained from public databases. No Institutional Review board Approval were needed.

Informed consent statement: The data was accessed in the database and all patients signed informed consent.

Conflict-of-interest statement: The authors declare that there are no conflicts of interests.

Data sharing statement: All data generated or analyzed during this study are included in this published article.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Zi-Wei Li 0000-0001-9759-4535; Fei Liu 0000-0002-4022-0732; Xu-Rui Liu 0000-0002-6069-2104; Xin-Peng Shu 0000-0003-0652-4772; Quan Lv 0009-0005-8861-0181; Xiao-Yu Liu 0000-0001-9448-4592; Wei Zhang 0000-0002-5822-9970; Dong Peng 0000-0003-4050-4337.

S-Editor: Lin C

L-Editor: A

P-Editor: Zhao S

REFERENCES

- 1 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer* 2019; **144**: 1941-1953 [PMID: 30350310 DOI: 10.1002/ijc.31937]
- 2 Peng D, Zou YY, Cheng YX, Tao W, Zhang W. Effect of Time (Season, Surgical Starting Time, Waiting Time) on Patients with Gastric Cancer. *Risk Manag Healthc Policy* 2021; **14**: 1327-1333 [PMID: 33824610 DOI: 10.2147/RMHP.S294141]
- 3 Kim YG, Kong SH, Oh SY, Lee KG, Suh YS, Yang JY, Choi J, Kim SG, Kim JS, Kim WH, Lee HJ, Yang HK. Effects of screening on gastric cancer management: comparative analysis of the results in 2006 and in 2011. *J Gastric Cancer* 2014; **14**: 129-134 [PMID: 25061541 DOI: 10.5230/jgc.2014.14.2.129]
- 4 Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. *World J Gastroenterol* 2014; **20**: 4483-4490 [PMID: 24782601 DOI: 10.3748/wjg.v20.i16.4483]
- 5 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; **20**: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]
- 6 Cheng YX, Tao W, Kang B, Liu XY, Yuan C, Zhang B, Peng D. Impact of Preoperative Type 2 Diabetes Mellitus on the Outcomes of Gastric Cancer Patients Following Gastrectomy: A Propensity Score Matching Analysis. *Front Surg* 2022; **9**: 850265 [PMID: 35350140 DOI: 10.3389/fsurg.2022.850265]
- 7 Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2022; **20**: 167-192 [PMID: 35130500 DOI: 10.6004/jncn.2022.0008]
- 8 Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. *J Clin Oncol* 2016; **34**: 1350-1357 [PMID: 26903580 DOI: 10.1200/JCO.2015.63.7215]
- 9 Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004; **22**: 2767-2773 [PMID: 15199090 DOI: 10.1200/jco.2004.10.184]
- 10 Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. *Am J Surg* 2002; **183**: 630-641 [PMID: 12095591 DOI: 10.1016/s0002-9610(02)00866-8]
- 11 Sugisawa N, Tokunaga M, Makuuchi R, Miki Y, Tanizawa Y, Bando E, Kawamura T, Terashima M. A phase II study of an enhanced recovery after surgery protocol in gastric cancer surgery. *Gastric Cancer* 2016; **19**: 961-967 [PMID: 26260875 DOI: 10.1007/s10120-015-0528-6]
- 12 Peng D, Cheng YX, Tao W, Tang H, Ji GY. Effect of enhanced recovery after surgery on inflammatory bowel disease surgery: A meta-analysis. *World J Clin Cases* 2022; **10**: 3426-3435 [PMID: 35611189 DOI: 10.12998/wjcc.v10.i11.3426]
- 13 Tanaka R, Lee SW, Kawai M, Tashiro K, Kawashima S, Kagota S, Honda K, Uchiyama K. Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial. *Gastric Cancer* 2017; **20**: 861-871 [PMID: 28062937 DOI: 10.1007/s10120-016-0686-1]
- 14 Cheng YX, Tao W, Liu XY, Yuan C, Zhang B, Zhang W, Peng D. The outcome of young vs. old gastric cancer patients following gastrectomy: a propensity score matching analysis. *BMC Surg* 2021; **21**: 399 [PMID: 34798854 DOI: 10.1186/s12893-021-01401-1]
- 15 Zhou Y, Liu S, Wang J, Yan X, Zhang L. Changes in blood glucose of elderly patients with gastric cancer combined with type 2 diabetes mellitus after radical operation and the effect of mediation adjustment for blood glucose on the recovery of gastric cancer. *Oncol Lett* 2018; **16**: 4303-4308 [PMID: 30214565 DOI: 10.3892/ol.2018.9197]
- 16 Kakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, Sasaki A, Takiguchi S, Takeuchi H, Hashimoto M, Horiguchi A, Masaki T, Marubashi S, Yoshida K, Gotoh M, Konno H, Yamamoto H, Miyata H, Seto Y, Kitagawa Y. National Clinical Database. Surgical outcomes in gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2018. *Ann Gastroenterol Surg* 2020; **4**: 250-274 [PMID: 32490340 DOI: 10.1002/ags3.12324]
- 17 Xiao SM, Ma HL, Xu R, Yang C, Ding Z. Enhanced Recovery After Surgery protocol for elderly gastric cancer patients: A prospective study for safety and efficacy. *Asian J Surg* 2022; **45**: 2168-2171 [PMID: 35031180 DOI: 10.1016/j.asjsur.2021.10.040]
- 18 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]
- 19 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]
- 20 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]
- 21 Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. *J Eval Clin Pract* 2008; **14**: 951-957 [PMID: 19018930 DOI: 10.1111/j.1365-2753.2008.00986.x]
- 22 Franceschilli M, Siragusa L, Usai V, Dhimolea S, Pirozzi B, Sibio S, Di Carlo S. Immunonutrition reduces complications rate and length of

- stay after laparoscopic total gastrectomy: a single unit retrospective study. *Discov Oncol* 2022; **13**: 62 [PMID: 35816241 DOI: 10.1007/s12672-022-00490-5]
- 23 **Weindelmayer J**, Mengardo V, Gasparini A, Sacco M, Torroni L, Carlini M, Verlato G, de Manzoni G. Enhanced Recovery After Surgery can Improve Patient Outcomes and Reduce Hospital Cost of Gastrectomy for Cancer in the West: A Propensity-Score-Based Analysis. *Ann Surg Oncol* 2021; **28**: 7087-7094 [PMID: 33988796 DOI: 10.1245/s10434-021-10079-x]
 - 24 **Cao S**, Zheng T, Wang H, Niu Z, Chen D, Zhang J, Lv L, Zhou Y. Enhanced Recovery after Surgery in Elderly Gastric Cancer Patients Undergoing Laparoscopic Total Gastrectomy. *J Surg Res* 2021; **257**: 579-586 [PMID: 32927324 DOI: 10.1016/j.jss.2020.07.037]
 - 25 **Liu G**, Jian F, Wang X, Chen L. Fast-track surgery protocol in elderly patients undergoing laparoscopic radical gastrectomy for gastric cancer: a randomized controlled trial. *Onco Targets Ther* 2016; **9**: 3345-3351 [PMID: 27330314 DOI: 10.2147/OTT.S107443]
 - 26 **Bu J**, Li N, Huang X, He S, Wen J, Wu X. Feasibility of Fast-Track Surgery in Elderly Patients with Gastric Cancer. *J Gastrointest Surg* 2015; **19**: 1391-1398 [PMID: 25943912 DOI: 10.1007/s11605-015-2839-7]
 - 27 **Wilmore DW**, Kehlet H. Management of patients in fast track surgery. *BMJ* 2001; **322**: 473-476 [PMID: 11222424 DOI: 10.1136/bmj.322.7284.473]
 - 28 **Taupyk Y**, Cao X, Zhao Y, Wang C, Wang Q. Fast-track laparoscopic surgery: A better option for treating colorectal cancer than conventional laparoscopic surgery. *Oncol Lett* 2015; **10**: 443-448 [PMID: 26171048 DOI: 10.3892/ol.2015.3166]
 - 29 **Mortensen K**, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, Carli F, Demartines N, Griffin SM, Lassen K; Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Br J Surg* 2014; **101**: 1209-1229 [PMID: 25047143 DOI: 10.1002/bjs.9582]
 - 30 **Zhao G**, Cao S, Cui J. Fast-track surgery improves postoperative clinical recovery and reduces postoperative insulin resistance after esophagectomy for esophageal cancer. *Support Care Cancer* 2014; **22**: 351-358 [PMID: 24068549 DOI: 10.1007/s00520-013-1979-0]
 - 31 **Lin JX**, Yi BC, Yoon C, Li P, Zheng CH, Huang CM, Yoon SS. Comparison of Outcomes for Elderly Gastric Cancer Patients at Least 80 Years of Age Following Gastrectomy in the United States and China. *Ann Surg Oncol* 2018; **25**: 3629-3638 [PMID: 30218243 DOI: 10.1245/s10434-018-6757-2]
 - 32 **Liu XR**, Liu XY, Zhang B, Liu F, Li ZW, Yuan C, Wei ZQ, Peng D. Enhanced recovery after colorectal surgery is a safe and effective pathway for older patients: a pooling up analysis. *Int J Colorectal Dis* 2023; **38**: 81 [PMID: 36964841 DOI: 10.1007/s00384-023-04377-x]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

